• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Infections associated with ruxolitinib: study in the French Pharmacovigilance database.

作者信息

Sylvine Pinel, Thomas Sternjacob, Pirayeh Eftekhari

机构信息

French Regional Pharmacovigilance Center, Fernand-Widal Hospital - APHP, 200, rue du faubourg SaintDenis, 75475, Paris, France.

出版信息

Ann Hematol. 2018 May;97(5):913-914. doi: 10.1007/s00277-018-3242-8. Epub 2018 Jan 16.

DOI:10.1007/s00277-018-3242-8
PMID:29340760
Abstract
摘要

相似文献

1
Infections associated with ruxolitinib: study in the French Pharmacovigilance database.与鲁索替尼相关的感染：法国药物警戒数据库研究
Ann Hematol. 2018 May;97(5):913-914. doi: 10.1007/s00277-018-3242-8. Epub 2018 Jan 16.
2
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.芦可替尼：一种新型 JAK1/2 抑制剂，为骨髓纤维化的治疗提供了有前景的选择。
Future Oncol. 2011 Sep;7(9):1035-43. doi: 10.2217/fon.11.81.
3
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.芦可替尼与最佳可用疗法治疗骨髓纤维化的 JAK 抑制作用比较。
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.
4
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.克服骨髓纤维化和真性红细胞增多症的治疗挑战：芦可替尼的作用
Cancer Chemother Pharmacol. 2016 Jun;77(6):1125-42. doi: 10.1007/s00280-016-3012-z. Epub 2016 Mar 26.
5
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704.
6
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2031-2; author reply 2032-4. doi: 10.1056/NEJMc1203704.
7
Ruxolitinib for myelofibrosis.芦可替尼用于治疗骨髓纤维化。
N Engl J Med. 2012 May 24;366(21):2031; author reply 2032-4. doi: 10.1056/NEJMc1203704.
8
Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data.芦可替尼治疗的骨髓纤维化患者发生的医源性卡波西肉瘤：病例报告、文献综述及法国药物警戒数据
Am J Hematol. 2022 Jan 1;97(1):E31-E34. doi: 10.1002/ajh.26398. Epub 2021 Nov 9.
9
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.哪些骨髓纤维化患者应接受芦可替尼治疗？ELN-SIE 循证推荐。
Leukemia. 2017 Apr;31(4):882-888. doi: 10.1038/leu.2016.283. Epub 2016 Oct 14.
10
Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.Janus激酶1/2抑制剂鲁索替尼对骨髓纤维化患者肺动脉高压和心脏功能的长期影响
Intern Med. 2020 Jan 15;59(2):229-233. doi: 10.2169/internalmedicine.3528-19. Epub 2019 Sep 18.

引用本文的文献

1
Pulmonary Coccidioidomycosis in a Ruxolitinib-Treated Polycythemia Vera Patient: A Case Study and Literature Review.芦可替尼治疗的真性红细胞增多症患者并发肺球孢子菌病：病例报告及文献综述
Cureus. 2025 Apr 4;17(4):e81725. doi: 10.7759/cureus.81725. eCollection 2025 Apr.
2
Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL).血液系统恶性肿瘤的原发性抗真菌预防。欧洲白血病感染会议（ECIL）更新的临床实践指南
Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02586-7.
3
Overview of infectious complications among CAR T- cell therapy recipients.
CAR-T细胞疗法接受者感染并发症概述。
Front Oncol. 2024 Jul 3;14:1398078. doi: 10.3389/fonc.2024.1398078. eCollection 2024.
4
Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer.JAK2/STAT3信号通路在三阴性乳腺癌中的潜在治疗靶点
Front Oncol. 2024 Apr 18;14:1381251. doi: 10.3389/fonc.2024.1381251. eCollection 2024.
5
Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.鲁索替尼治疗的骨髓纤维化患者发生播散性组织胞浆菌病：一例报告及鲁索替尼相关侵袭性真菌感染的文献综述
J Fungi (Basel). 2024 Mar 31;10(4):264. doi: 10.3390/jof10040264.
6
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients.在再生障碍性贫血患者进行异基因干细胞移植时，添加鲁索利替尼以预防标准移植物抗宿主病。
Bone Marrow Transplant. 2024 Jul;59(7):997-1005. doi: 10.1038/s41409-024-02266-7. Epub 2024 Apr 5.
7
Disseminated Complex Myositis in a Patient With Graft-Versus-Host Disease.一名患有移植物抗宿主病患者的播散性复杂性肌炎
Open Forum Infect Dis. 2022 Jul 29;9(8):ofac385. doi: 10.1093/ofid/ofac385. eCollection 2022 Aug.
8
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.血液系统恶性肿瘤中的侵袭性真菌感染与靶向治疗
J Fungi (Basel). 2021 Dec 10;7(12):1058. doi: 10.3390/jof7121058.
9
Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors.接受 JAK 抑制剂治疗的 MPN 患者的免疫失调和感染并发症。
Front Immunol. 2021 Nov 19;12:750346. doi: 10.3389/fimmu.2021.750346. eCollection 2021.
10
A Case of Hepatitis E Persistence in a Patient With Myelofibrosis Under Ruxolitinib.一例接受鲁索替尼治疗的骨髓纤维化患者戊型肝炎持续感染病例
ACG Case Rep J. 2021 Nov 19;8(11):e00674. doi: 10.14309/crj.0000000000000674. eCollection 2021 Nov.